DDInter93 DDInter1294
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Anagrelide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Anagrelide {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Flutamide
Flutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) interacts with {v} (Gene) POR
POR {u} (Gene) is bound by {v} (Compound) Nilutamide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nilutamide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Nilutamide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Anagrelide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Anagrelide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Nilutamide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Anagrelide (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Flutamide (Compound) and Flutamide (Compound) resembles Nilutamide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) interacts with POR (Gene) and POR (Gene) is bound by Nilutamide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Nilutamide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Nilutamide (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide (Compound) resembles Nilutamide (Compound)